Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Neoplasms × giredestrant × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Endometrial Neoplasms 1

Interventions

Paclitaxel 96 Carboplatin 90 pembrolizumab 52 Bevacizumab 50 liposomal doxorubicin 48 olaparib 34 Gemcitabine 31 niraparib 28 Topotecan 25 Nivolumab 20 Cisplatin 19 Doxorubicin 16 Drug Therapy 14 Docetaxel 14 1-dodecylpyridoxal 13 Cyclophosphamide 12 avelumab 11 Fulvestrant 10 oregovomab 9 veliparib 8 atezolizumab 8 Oxaliplatin 8 Cetuximab 8 rucaparib 7 mirvetuximab soravtansine 7 fluzoparib 7 Injections 7 Fluorouracil 7 130-nm albumin-bound paclitaxel 7 trebananib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04931342 2026-03-10

BOUQUET

Hoffmann-La Roche

Phase 2 Active not recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡